tiprankstipranks
Advertisement
Advertisement

NURPF Stock Latest News

Neuren Cancels Shares Following On-Market Buy-Back
Company AnnouncementsNeuren Cancels Shares Following On-Market Buy-Back
2d ago
Neuren Expands Rett Syndrome Reach as DAYBUE STIX Goes Broadly U.S.-Available
PremiumCompany Announcements
Neuren Expands Rett Syndrome Reach as DAYBUE STIX Goes Broadly U.S.-Available
4d ago
Neuren Pharmaceuticals Reports Lapse of 50,000 Conditional Options
PremiumCompany Announcements
Neuren Pharmaceuticals Reports Lapse of 50,000 Conditional Options
17d ago
Neuren updates market on ongoing on‑market share buy‑back
PremiumCompany Announcements
Neuren updates market on ongoing on‑market share buy‑back
19d ago
Neuren Updates Market on Ongoing On-Market Share Buy-Back
PremiumCompany Announcements
Neuren Updates Market on Ongoing On-Market Share Buy-Back
1M ago
Neuren director Joseph Basile lifts stake with on-market share purchase
PremiumCompany AnnouncementsNeuren director Joseph Basile lifts stake with on-market share purchase
1M ago
Neuren backs Acadia’s EMA appeal after CHMP rejection of Rett drug trofinetide
Premium
Company Announcements
Neuren backs Acadia’s EMA appeal after CHMP rejection of Rett drug trofinetide
1M ago
Neuren Highlights Neurodevelopmental Focus and Development Risks in Investor Update
Premium
Company Announcements
Neuren Highlights Neurodevelopmental Focus and Development Risks in Investor Update
1M ago
Neuren Builds Cash and Pipeline as DAYBUE Royalties Climb in 2025
PremiumCompany Announcements
Neuren Builds Cash and Pipeline as DAYBUE Royalties Climb in 2025
1M ago
Neuren profit falls on absence of one-offs as core royalties and R&D spend climb
PremiumCompany Announcements
Neuren profit falls on absence of one-offs as core royalties and R&D spend climb
1M ago
Neuren Rides DAYBUE Growth as 2025 Royalties Climb and 2026 Outlook Strengthens
PremiumCompany Announcements
Neuren Rides DAYBUE Growth as 2025 Royalties Climb and 2026 Outlook Strengthens
2M ago
Neuren Pharmaceuticals Launches On-Market Share Buy-Back
PremiumCompany Announcements
Neuren Pharmaceuticals Launches On-Market Share Buy-Back
2M ago
Neuren Schedules Investor Webinar as Rare Neurology Portfolio Advances
PremiumCompany AnnouncementsNeuren Schedules Investor Webinar as Rare Neurology Portfolio Advances
2M ago
Neuren launches on-market buy-back as board flags undervalued shares
Premium
Company Announcements
Neuren launches on-market buy-back as board flags undervalued shares
2M ago
Neuren Doses First Patient in Landmark Phase 3 Trial for Phelan-McDermid Syndrome
Premium
Company Announcements
Neuren Doses First Patient in Landmark Phase 3 Trial for Phelan-McDermid Syndrome
2M ago
Neuren Set to Benefit as US Extends Rare Pediatric Disease Voucher Program to 2029
PremiumCompany Announcements
Neuren Set to Benefit as US Extends Rare Pediatric Disease Voucher Program to 2029
2M ago
Neuren Gains FDA Feedback Charting NNZ-2591 Path in HIE and Pitt Hopkins
PremiumCompany Announcements
Neuren Gains FDA Feedback Charting NNZ-2591 Path in HIE and Pitt Hopkins
2M ago
Neuren Faces EU Setback as EMA Panel Issues Negative Trend Vote on Trofinetide for Rett Syndrome
PremiumCompany Announcements
Neuren Faces EU Setback as EMA Panel Issues Negative Trend Vote on Trofinetide for Rett Syndrome
2M ago
Neuren Defends Timely Disclosure of Material DAYBUE Sales Projections to ASX
PremiumCompany Announcements
Neuren Defends Timely Disclosure of Material DAYBUE Sales Projections to ASX
3M ago
Neuren’s Partner Acadia Sees DAYBUE Sales Climbing to US$700m by 2028
PremiumCompany AnnouncementsNeuren’s Partner Acadia Sees DAYBUE Sales Climbing to US$700m by 2028
3M ago
Neuren’s Phase 3 NNZ-2591 Trial Targets a High-Value Niche in Phelan-McDermid Syndrome
Premium
Company Announcements
Neuren’s Phase 3 NNZ-2591 Trial Targets a High-Value Niche in Phelan-McDermid Syndrome
3M ago
NURPF
Neuren Advances NNZ-2591 Program as Phase 2 PMS Data Published and Phase 3 Koala Trial Recruits in US
Premium
Company Announcements
Neuren Advances NNZ-2591 Program as Phase 2 PMS Data Published and Phase 3 Koala Trial Recruits in US
3M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >